Moore, K, Chan, JK, Secord, AA, Patel, MR, Callahan, T, Guo, W, and Zhang, Z-Y. "Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.(Accepted)" Cancer Chemotherapy and Pharmacology 83, no. 4 (April 2019): 717-726.
Angeles Alvarez Secord, MD
My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.
Education and Training
- Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
- M.D., University of Washington, 1994
- Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011
Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment.
Selected Grants and Awards
- SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
- A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician¿s Choice in Participants with Adva
- Atezo NACT for Ovarian Cancer
- GOG 3018: OVAL
- GOG 3025: DUO-O
- GOG 3020: ATHENA
- Atezo NACT for Ovarian Cancer (Bio- Markers Lab Clinc Resch)
- GOG3015 Foundation Study ( Atezo Frontline)
- Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
- Tapimmune FRV-004
- GOG3005-ABB VIE Protocol M13-694
- A Phase 2 Randomized Double-Blind Trial of Maintenance with Niraparib vs Placebo
- A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Cancers of Muellerian Origin
- NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
- Quadra Study
- NCI National Clinical Trials Network U10 (Year 5)
- Women with BRCA-mutated Advanced Stage Ovarian Cancer
- GOG3016 Foundation Study ( Atezo Frontline)
- Apera ARP-407
- Lynparza Open Acess Olaparib
- Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer
- Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients
- Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer
- Tesaro Ovarian Cancer Practicum
- A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy
Previs, RA, and Secord, AA. "Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management." Obstetrics and Gynecology Clinics of North America 46, no. 1 (March 2019): 67-88. (Review)
Foote, JR, Secord, AA, Liang, MI, Ehrisman, JA, Cohn, DE, Jewell, E, and Havrilesky, LJ. "Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer." Gynecologic Oncology 152, no. 3 (March 1, 2019): 445-451.
Lim, SL, Havrilesky, LJ, Habib, AS, and Secord, AA. "Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy." Gynecologic Oncology (February 2019).
Rose, PG, Java, JJ, Salani, R, Geller, MA, Secord, AA, Tewari, KS, Bender, DP, Mutch, DG, Friedlander, ML, Van Le, L, Method, MW, Hamilton, CA, Lee, RB, Wenham, RM, Guntupalli, SR, Markman, M, Muggia, FM, Armstrong, DK, Bookman, MA, Burger, RA, and Copeland, LJ. "Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma." Obstetrics and Gynecology 133, no. 2 (February 2019): 245-254.
Puechl, AM, Edwards, J, Suri, A, Nakayama, J, Bean, S, Gehrig, P, Saks, E, Duska, L, Broadwater, G, Ehrisman, J, Horowitz, N, and Secord, AA. "The association between progesterone receptor expression and survival in women with adult granulosa cell tumors." Gynecologic Oncology (January 17, 2019).
Davidson, BA, Broadwater, G, Crim, A, Boccacio, R, Bixel, K, Backes, F, Previs, RA, Salinaro, J, Salani, R, Moore, K, and Secord, AA. "Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy." Gynecologic Oncology (December 14, 2018).
Monk, BJ, Kauderer, JT, Moxley, KM, Bonebrake, AJ, Dewdney, SB, Secord, AA, Ueland, FR, Johnston, CM, and Aghajanian, C. "A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study." Gynecologic Oncology 151, no. 3 (December 2018): 422-427.
Lim, SL, Moss, HA, Secord, AA, Lee, PS, Havrilesky, LJ, and Davidson, BA. "Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis." Gynecologic Oncology 151, no. 3 (December 2018): 506-512.
Tew, WP, Sill, MW, Walker, JL, Secord, AA, Bonebrake, AJ, Schilder, JM, Stuckey, A, Rice, L, Tewari, KS, and Aghajanian, CA. "Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study." Gynecologic Oncology 151, no. 2 (November 2018): 257-263.